Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Scientific discussion for the approval of Masivet
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Temporal trends in the incidence of multiple sclerosis: a systematic review.
Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial.
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination.
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.
Transfer of interferon β-1a into human breastmilk.
T(H)17 cytokines in autoimmune neuro-inflammation.
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.
The natural history of primary progressive MS in British Columbia, Canada.
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS.
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Neuroprotective effects of testosterone treatment in men with multiple sclerosis.
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
Demyelination of the hippocampus is prominent in the cuprizone model.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.

Pages